ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "interstitial lung disease"

  • Abstract Number: 1659 • ACR Convergence 2022

    FAM13A (Family with Sequence Similarity 13 Member A) Polymorphism Is Associated with Presence of a Radiographic Usual Interstitial Pneumonia Pattern in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

    Elana Bernstein1, Francesco Boin2, Brett Elicker3, Yawen Ren4, John Varga5 and Shervin Assassi6, 1Columbia University, New York, NY, 2Cedars-Sinai Medical Center, Los Angeles, CA, 3University of California San Francisco, San Francisco, CA, 4University of Texas Health Science Center at Houston, Houston, TX, 5University of Michigan, Ann Arbor, MI, 6McGovern Medical School, University of Texas, Houston, TX

    Background/Purpose: The pathogenesis of SSc-associated interstitial lung disease (ILD) is incompletely understood. The MUC5B promoter gain-of-function single nucleotide polymorphism (SNP) rs35705950 has been associated with…
  • Abstract Number: 2249 • ACR Convergence 2022

    Impact of Interstitial Lung Disease on COVID-19 Severity Among Patients with Rheumatoid Arthritis: A Multicenter Comparative Study

    Gabriel Figueroa Parra1, Emily Gilbert2, Maria Valenzuela Almada1, Sebastian Vallejo1, Matthew Neville3, Naomi Patel4, Claire Cook5, Xiaoqing Fu5, Ramla Hagi5, Gregory McDermott6, Michael Dilorio6, Lucy Masto6, Kathleen Vanni6, Emily Kowalski6, Grace Qian6, Zachary Wallace5, Ali Duarte-Garcia1 and Jeffrey Sparks7, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Jacksonville, FL, 3Mayo Clinic, Phoenix, AZ, 4Massachusetts General Hospital, Sale Creek, TN, 5Massachusetts General Hospital, Boston, MA, 6Brigham and Women's Hospital, Boston, MA, 7Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Rheumatoid arthritis (RA) has been associated with severe COVID-19, but few studies have investigated outcomes in RA phenotypes such as interstitial lung disease (RA-ILD),…
  • Abstract Number: 0245 • ACR Convergence 2022

    Influence of Forced Vital Capacity Impairment on Treatment Selection and Outcomes in RA-ILD Patients Initiating a Biologic or Targeted-Synthetic DMARD

    Bryant England1, Michael George2, Yangyuna Yang1, Punyasha Roul3, Jorge Rojas4, Brian Sauer5, Grant Cannon6, Joshua Baker7, Jeffrey Curtis8 and Ted Mikuls9, 1University of Nebraska Medical Center, Omaha, NE, 2University of Pennsylvania, Philadelphia, PA, 3UNMC, Omaha, NE, 4George E. Wahlen Department of Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, 5Salt Lake City VA/University of Utah, Salt Lake City, UT, 6Salt Lake City VA, Salt Lake city, 7University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, 8Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 9Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Patients with RA-associated interstitial lung disease (RA-ILD) suffer from substantial morbidity and premature mortality. The optimal use of biologic/tsDMARDs in this population is poorly…
  • Abstract Number: 0920 • ACR Convergence 2022

    Retention Rate and Safety of Biologic or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs (DMARDs) in Patients with Rheumatoid Arthritis Associated with Interstitial Lung Disease: Results from the KOBIO Registry

    Ji-Won Kim1, Sun-Kyung Lee2, Ju-Yang Jung1, Chang-Hee Suh3, Kichul Shin4 and Hyoun-Ah Kim1, 1Ajou University School of Medicine, Suwon, Republic of Korea, 2Hanyang university, Seoul, Republic of Korea, 3Ajou University Hospital, Suwon, Republic of Korea, 4Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, Republic of Korea

    Background/Purpose: The aim was to evaluate long-term drug retention and safety of biologic (bDMARDs) or targeted synthetic disease modifying anti-rheumatic drugs (tsDMARDs) and to identify…
  • Abstract Number: 1231 • ACR Convergence 2022

    [68Ga]- CPCR4 Trifluoroacetate PET/CT Imaging of Chemokine Receptor CXCR4- Expression in Systemic Sclerosis Related Interstitial Lung Disease

    Chirag Rajkumar Kopp1, Shefali Sharma2, Venkata Subramanian Krishnaraju3, Chandra Bhushan Prasad3, Jagdeep Singh3, Shashi Anand3, Ranjana Minz3, Ashwani Sood3, Anindita Sinha3, Rajender Kumar Basher3, Sahajal Dhooria3, Varun Dhir4 and sanjay jain3, 1Post Graduate Institute of Medical Education and Research, Chandigarh, India, 2PGIMER< Chandigarh, Chandigarh, India, 3Postgraduate Institute of Medical Education and Research, Chandigarh, India, 4PGIMER, CHD, INDIA, Chandigarh, India

    Background/Purpose: Interstitial lung disease (ILD) in Systemic sclerosis (SSc) is a major contributor of morbidity and mortality. CXCR4/CXCL12 axis has been implicated in the pathogenesis…
  • Abstract Number: 1855 • ACR Convergence 2022

    Clinical Outcomes in an Observational Retrospective Cohort of Patients with Connective Tissue Disease-associated Interstitial Lung Disease (CTD-ILD) Who Taper Immunosuppressive Therapy

    Paul Dellaripa, Paul Hoover and Tracy Doyle, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Patients with CTD-ILD are often treated with a combination of corticosteroids and steroid sparing agents to limit the progression of the inflammatory response in…
  • Abstract Number: 2250 • ACR Convergence 2022

    Genetic and Environmental Risk Factors in Rheumatoid Arthritis-Associated Interstitial Lung Disease

    Austin Wheeler1, Yangyuna Yang1, Joshua Baker2, Jill Poole1, Dana Ascherman3, Gail Kerr4, Andreas Reimold5, Gary Kunkel6, Grant Cannon7, Katherine Wysham8, Namrata Singh9, Deana Lazaro10, Paul Monach11, S. Louis Bridges, Jr.12, Ted Mikuls13 and Bryant England1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Pennsylvania, Philadelphia, PA, 3University of Pittsburgh, Pittsburgh, PA, 4Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 5University of Texas Southwestern Medical Center, Dallas, TX, 6University of Utah, Salt Lake City, UT, 7Retired, Salt Lake City, UT, 8VA Puget Sound/University of Washington, Seattle, WA, 9University of Washington, Bellevue, WA, 10VA New York Harbor Healthcare system, Short Hills, NJ, 11VA Boston Healthcare System, Boston, MA, 12Hospital for Special Surgery, New York, NY, 13Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: RA-associated interstitial lung disease (RA-ILD) is an extra-articular manifestation of RA causing substantial morbidity and mortality. Genetic risk variants, such as the MUC5B rs35705950…
  • Abstract Number: 0248 • ACR Convergence 2022

    Monocyte Chemoattractant Protein-1, Vascular Cell Adhesion Protein-1 and Asymmetric Dimethylarginine as Potential Biomarkers of Interstitial Lung Disease Associated with RA

    Veronica Pulito-Cueto1, Sara Remuzgo-Martinez1, Fernanda Genre1, Belén Atienza-Mateo1, Víctor M. Mora-Cuesta1, David Iturbe-Fernández1, Leticia Lera-Gómez1, Diana Prieto-Peña1, Virgi Portilla1, Ricardo Blanco2, Alfonso Corrales1, Oreste Gualillo3, José M. Cifrián1, Raquel Lopez Mejias4 and Miguel Ángel González-Gay5, 1Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 3Hospital Clínico Universitario de Santiago, SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), NEIRID Lab (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Research Laboratory 9, Santiago de Compostela, Spain, 4IDIVAL, Santander, Spain, 5Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

    Background/Purpose: Interstitial lung disease (ILD) is one of the main comorbidities of patients with RA contributing to an increased mortality risk [1]. The pathogenesis of…
  • Abstract Number: 1047 • ACR Convergence 2022

    A Novel Prediction Tool for Progression of Systemic Sclerosis-Interstitial Lung Disease Despite Treatment with Immunosuppression

    Elizabeth Volkmann1, Holly Wilhalme1, Grace Kim1, Jonathan Goldin1, Shervin Assassi2, Masataka Kuwana3, Donald Tashkin1 and Michael roth1, 1University of California Los Angeles, Los Angeles, CA, 2McGovern Medical School, University of Texas, Houston, TX, 3Nippon Medical School Graduate School of Medicine, Tokyo, Japan

    Background/Purpose: Systemic sclerosis-interstitial lung disease (SSc-ILD) is the leading cause of SSc-related death. While some patients respond favorably to treatment with immunosuppression, a subset of…
  • Abstract Number: 1246 • ACR Convergence 2022

    Improving Radiologic Interpretation of Diffuse Lung Disease in Pediatric Rheumatologic (PR) Patients Using Trained Scoring with Semi-quantitative Chest Computed Tomography (CT) Analysis

    Michal Cidon1, Beverley Newman2, Terry Robinson3, Paul Iskander4, Paul Thacker5, Evan Zucker2, Tzielan Lee6 and Rex Moats3, 1Children's Hospital Los Angeles, Los Angeles, CA, 2Stanford Children's Health, Stanford, CA, 3Children's Hospital of Los Angeles, Los Angeles, CA, 4University of California Los Angeles, Los Angeles, CA, 5Mayo Clinic, Rochester, MN, 6Stanford University School of Medicine, Palo Alto, CA

    Background/Purpose: We presented preliminary data in 2021 to support the feasibility of using a semi-quantitative chest CT scoring system (Pediatric Rheumatologic Diffuse Lung Disease Score…
  • Abstract Number: 1857 • ACR Convergence 2022

    Increasing Proportion of MDA-5 Associated Conditions in a Tertiary Myositis Centre Following Onset of the Covid-19 Pandemic

    Jennifer Hannah1, Saadia Sasha Ali1, Sloni Arora1, John Cazabon1, James Galloway1 and Patrick Gordon2, 1King's College London, London, United Kingdom, 2King’s College Hospital NHS Foundation Trust, London, United Kingdom

    Background/Purpose: Anti-MDA5 dermatomyositis is a clinical subtype of DM that is strongly associated with a rapidly progressive phenotype of interstitial lung disease resulting in a…
  • Abstract Number: 2251 • ACR Convergence 2022

    Reduction in Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk in Patients Treated with Tofacitinib

    Matthew Baker1, Yuhan Liu1, Rong Lu1, Janice Lin1, Jason Melehani1 and William Robinson2, 1Stanford University, Stanford, CA, 2Stanford University School of Medicine, Palo Alto, CA

    Background/Purpose: Clinically significant interstitial lung disease (ILD) occurs in roughly 10% of patients with rheumatoid arthritis (RA). There are limited data on the pathogenesis of…
  • Abstract Number: 0249 • ACR Convergence 2022

    Identification of Distinct Peripheral Blood Myeloid Cell Subpopulations in Patients with Rheumatoid Arthritis-associated Interstitial Lung Disease

    Jill Poole1, Bryant England1, Kathryn Cole1, James Talmadge1, Amy Nelson1, Rohit Gaurav1, Aaron Schwabb1, Angela Gleason1, Michael Duryee1, Rhonda Walenz1, Bridget Kramer1, Joel VanDeGraaff1, Sara May1, Geoffrey Thiele1 and Ted Mikuls2, 1University of Nebraska Medical Center, Omaha, NE, 2Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Interstitial lung disease (ILD) is associated with significant morbidity and mortality in rheumatoid arthritis (RA). The key cellular players of RA-ILD remain largely unknown.…
  • Abstract Number: 1048 • ACR Convergence 2022

    Nailfold Capillaroscopy and Candidate Biomarker Levels in Systemic Sclerosis-associated Pulmonary Hypertension, Profiling of Non-invasive Markers: A Cross Sectional Study

    Jacqueline Lemmers1, Arjan van Caam2, Brigit Kersten2, Els Ende, van den2, Hanneke KNAAPEN2, Arie Dijk, van2, Wanda Hagmolen of ten Have2, Frank van den Hoogen2, Hans Koenen2, Sander van Leuven3, wynand Alkema4, Ruben Smeets2 and Madelon Vonk5, 1Radboud University Medical Centre Nijmegen, Nijmegen, Netherlands, 2Radboudumc, Nijmegen, Netherlands, 3Radboud University, Nijmegen, Netherlands, 4Hanze University, Groningen the Netherlands, Dept. Data Science for Life Sciences & Health, Groningen, Netherlands, 5Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands

    Background/Purpose: Pulmonary hypertension (PH) is one of the leading causes of death in Systemic Sclerosis (SSc). Early detection and treatment of PH in SSc is…
  • Abstract Number: 1247 • ACR Convergence 2022

    Lung Ultrasound in Patients with Connective Tissue Disease-associated Interstitial Lung Disease; Utility of Single Evaluation in Clinical Practice

    Shinji Watanabe1, Keina Yomono2, Mikito Suzuki2, Nobuhito Sasaki2, Takahisa Gono2 and Masataka Kuwana2, 1Nippon Medical School Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan, 2Nippon Medical School Graduate School of Medicine, Tokyo, Japan

    Background/Purpose: Utility of lung ultrasound (LUS) in evaluation of interstitial lung disease (ILD) has recently attracted attention because of handiness and low invasiveness. The majority…
  • « Previous Page
  • 1
  • …
  • 26
  • 27
  • 28
  • 29
  • 30
  • …
  • 47
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology